Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

BACKGROUND: In Japan, the clinical efficacy of erlotinib monotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer was demonstrated in the phase II JO22903 trial, which reported a median progression-free survival of 11.8 months. Here we report final overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Noboru, Goto, Koichi, Nishio, Makoto, Chikamori, Kenichi, Hida, Toyoaki, Maemondo, Makoto, Katakami, Nobuyuki, Kozuki, Toshiyuki, Yoshioka, Hiroshige, Seto, Takashi, Tajima, Kosei, Tamura, Tomohide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306267/
https://www.ncbi.nlm.nih.gov/pubmed/27659294
http://dx.doi.org/10.1007/s10147-016-1039-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306267/
https://www.ncbi.nlm.nih.gov/pubmed/27659294
http://dx.doi.org/10.1007/s10147-016-1039-0

Ejemplares similares